My latest Clinical Pipeline column for is a look at zuranolone, a new antidepressant developed by Sage & Biogen, targeting the GABA pathway.

nature.com/articles/d41591-023

@cyrilpedia Nice article. Is Zuranolone an agonist or modulator of the receptor? You use both terms in the article. It could, perhaps, be both, although the latter is more likely.

Follow

@andrewplested It's a positive allosteric regulator - sorry for the confusion (I meant agonist in the sense that it activates the channel, but in the strict sense it does not mimic the natural ligand).

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.